Tearsheet

LeMaitre Vascular (LMAT)

Market Price (12/25/2025): $84.32 | Market Cap: $1.9 Bil
Sector: Health Care | Industry: Health Care Equipment

LeMaitre Vascular (LMAT)

Market Price (12/25/2025): $84.32
Market Cap: $1.9 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 26x, P/EPrice/Earnings or Price/(Net Income) is 36x
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 27%	Key risks LMAT key risks include [1] navigating complex, Show more.
2	Low stock price volatility Vol 12M is 33%
3	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management.

0	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 27%
2	Low stock price volatility Vol 12M is 33%
3	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management.
4	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 26x, P/EPrice/Earnings or Price/(Net Income) is 36x
5	Key risks LMAT key risks include [1] navigating complex, Show more.

Valuation, Metrics & Events

	12/25/25	2024	2023	2022	2021
Share Price CYE	$84.32	$91.29	$55.79	$44.78	$48.36
Market Cap CYE ($ Bil)	1.9	2.1	1.2	1.0	1.1
Total Debt ($ Bil)	0.2	0.2	0.0	0.0	0.0
Total Cash ($ Bil)	0.3	0.3	0.1	0.1	0.1
Enterprise Value ($ Bil)	1.8	2.3	1.2	1.0	1.1
Valuation Ratios
P/S TTM	7.9	9.4	6.5	6.3	6.9
P/EBIT TTM	26.2	36.2	31.9	36.8	29.1
P/E TTM	35.8	47.0	41.9	49.0	39.5
P/FCF TTM	28.9	55.7	42.8	45.7	35.2
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.4	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/25/25	2024	2023
Share Price CYE	$84.32	$91.29	$55.79
Market Cap CYE ($ Bil)	1.9	2.1	1.2
Total Debt ($ Bil)	0.2	0.2	0.0
Total Cash ($ Bil)	0.3	0.3	0.1
Enterprise Value ($ Bil)	1.8	2.3	1.2
Valuation Ratios
P/S TTM	7.9	9.4	6.5
P/EBIT TTM	26.2	36.2	31.9
P/E TTM	35.8	47.0	41.9
P/FCF TTM	28.9	55.7	42.8
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9
P/EBIT TTM (Sector)	-1.4	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	LMAT	S&P 500
REVENUE GROWTH	GOOD
Rev LTM ($ Bil)	0.2
Rev Chg Q	11.4%	7.3%
Rev Chg LTM	13.1%	6.1%
Rev Chg 3Y Avg	14.6%	5.5%
PROFITABILITY	VERY GOOD
Op Inc LTM ($ Bil)	0.1
CFO LTM ($ Bil)	0.1
Net Inc LTM ($ Bil)	0.1
Op Mgn LTM	25.7%	18.8%
CFO/Rev LTM	30.4%	20.4%
Net Inc Mgn	22.1%	13.1%
VALUATION	HIGH
P/S	7.9	3.2
P/CFO	26.1	15.7
P/FCF	28.9	20.6
P/E	35.8	23.5
STABILITY	VERY GOOD
Debt/Equity	0.10	0.21
Cash/Assets	0.57	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Sales Representatives	152	9302025	Link
Headcount	633	9302025	Link
Number of hospital accounts	5300	6302025	Link
Number of vascular surgeon users	12000	6302025	Link

Upcoming
2/26/2026	Earnings Release	Rev: - EPS: -

LMAT Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

1. LeMaitre Vascular's Q3 2025 Revenue Miss. On November 6, 2025, LeMaitre Vascular reported third-quarter 2025 revenue of $61.0 million, which fell short of analysts' consensus expectations of $62.23 million, potentially contributing to negative investor sentiment despite an adjusted earnings per share beat.

2. Analyst Downgrades and Price Target Reductions. Several analyst firms revised their ratings and price targets for LMAT during the period. Wells Fargo lowered its price target for the stock from $97.00 to $93.00 on November 7, 2025, and Wall Street Zen downgraded LeMaitre Vascular from a "buy" to a "hold" rating on December 6, 2025. These actions likely contributed to the stock's downward pressure.

Show more

Stock Movement Drivers

Fundamental Drivers

The -3.7% change in LMAT stock from 9/24/2025 to 12/24/2025 was primarily driven by a -14.8% change in the company's P/E Multiple.

	9242025	12242025	Change
Stock Price ($)	87.60	84.34	-3.72%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	234.64	240.87	2.65%
Net Income Margin (%)	20.08%	22.14%	10.28%
P/E Multiple	42.04	35.83	-14.78%
Shares Outstanding (Mil)	22.61	22.66	-0.20%
Cumulative Contribution			-3.72%

LTM = Last Twelve Months as of date shown

Market Drivers

9/24/2025 to 12/24/2025

	Return	Correlation
LMAT	-3.7%
Market (SPY)	4.4%	17.1%
Sector (XLV)	14.2%	37.5%

Fundamental Drivers

The 0.2% change in LMAT stock from 6/25/2025 to 12/24/2025 was primarily driven by a 10.9% change in the company's Net Income Margin (%).

	6252025	12242025	Change
Stock Price ($)	84.17	84.34	0.20%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	226.26	240.87	6.46%
Net Income Margin (%)	19.96%	22.14%	10.94%
P/E Multiple	42.06	35.83	-14.82%
Shares Outstanding (Mil)	22.57	22.66	-0.40%
Cumulative Contribution			0.20%

LTM = Last Twelve Months as of date shown

Market Drivers

6/25/2025 to 12/24/2025

	Return	Correlation
LMAT	0.2%
Market (SPY)	14.0%	28.4%
Sector (XLV)	16.9%	31.1%

Fundamental Drivers

The -8.1% change in LMAT stock from 12/24/2024 to 12/24/2025 was primarily driven by a -28.2% change in the company's P/E Multiple.

	12242024	12242025	Change
Stock Price ($)	91.78	84.34	-8.10%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	213.03	240.87	13.07%
Net Income Margin (%)	19.40%	22.14%	14.17%
P/E Multiple	49.92	35.83	-28.23%
Shares Outstanding (Mil)	22.48	22.66	-0.82%
Cumulative Contribution			-8.11%

LTM = Last Twelve Months as of date shown

Market Drivers

12/24/2024 to 12/24/2025

	Return	Correlation
LMAT	-8.1%
Market (SPY)	15.8%	39.2%
Sector (XLV)	13.3%	29.1%

Fundamental Drivers

The 89.3% change in LMAT stock from 12/25/2022 to 12/24/2025 was primarily driven by a 67.5% change in the company's Net Income Margin (%).

	12252022	12242025	Change
Stock Price ($)	44.56	84.34	89.27%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	160.20	240.87	50.35%
Net Income Margin (%)	13.22%	22.14%	67.46%
P/E Multiple	46.24	35.83	-22.52%
Shares Outstanding (Mil)	21.98	22.66	-3.07%
Cumulative Contribution			89.09%

LTM = Last Twelve Months as of date shown

Market Drivers

12/25/2023 to 12/24/2025

	Return	Correlation
LMAT	50.7%
Market (SPY)	48.9%	37.2%
Sector (XLV)	18.8%	29.5%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
LMAT Return	14%	25%	-7%	25%	64%	-8%	148%
Peers Return	1%	20%	-32%	6%	9%	27%	21%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	115%
Monthly Win Rates [3]
LMAT Win Rate	58%	50%	42%	67%	67%	42%
Peers Win Rate	50%	47%	42%	52%	47%	57%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
LMAT Max Drawdown	-41%	-1%	-22%	-3%	-5%	-15%
Peers Max Drawdown	-39%	-14%	-47%	-23%	-22%	-15%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ANGO, AORT, TFX, PEN, MDT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)

How Low Can It Go

Unique Key	Event	LMAT	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-38.3%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	62.2%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	360 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-45.3%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	82.9%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	239 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-46.3%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	86.4%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	701 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-75.7%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	311.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1,770 days	1,480 days

Compare to EW, MASI, ATRC, UFPT, DAVI

In The Past

LeMaitre Vascular's stock fell -38.3% during the 2022 Inflation Shock from a high on 6/25/2021. A -38.3% loss requires a 62.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About LeMaitre Vascular (LMAT)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

AI Analysis | Feedback

1. Boston Scientific for peripheral vascular devices.

2. The Stryker of vascular surgery tools and implants.

AI Analysis | Feedback

Vascular Grafts: Biomaterial tubes used to bypass or replace diseased blood vessels, primarily in the peripheral vasculature.
Embolectomy Catheters: Balloon-tipped catheters designed to remove thrombi and emboli from arteries.
Vascular Patches: Biologic or synthetic patches used to repair or enlarge blood vessels during vascular surgery.
CryoTherapy Devices: Systems that use extreme cold to ablate and treat incompetent saphenous veins for venous reflux disease.
Angioplasty Balloons & Peripheral Stents: Devices used to open narrowed or blocked peripheral arteries and maintain vessel patency.
Atherectomy Devices: Specialized catheters designed to remove atherosclerotic plaque from peripheral arteries.

AI Analysis | Feedback

LeMaitre Vascular (LMAT) primarily sells its medical devices to other companies and healthcare institutions, not directly to individuals.

The company designs, develops, manufactures, and markets products used in the treatment of peripheral vascular disease. Its customers are the healthcare providers where surgical and interventional procedures are performed. These include:

Hospitals: These are the primary sites for complex vascular surgeries and interventional procedures where LeMaitre Vascular's devices are utilized by vascular surgeons, interventional cardiologists, and interventional radiologists.
Ambulatory Surgical Centers (ASCs): For less complex or outpatient vascular procedures, ASCs also serve as a customer base for LeMaitre Vascular's product lines.
Clinics: Specialized vascular clinics or diagnostic centers that perform interventional procedures may also be customers.

LeMaitre Vascular typically sells its products directly to these healthcare facilities in the United States and internationally, as well as through independent distributors in some regions. Due to the distributed nature of its sales across thousands of healthcare providers globally, the company does not typically disclose specific named "major customer companies" (e.g., specific hospital systems or distributors) that constitute a material portion of its revenue. Therefore, it is not possible to list specific public companies as major customers with their symbols.

AI Analysis | Feedback

null

AI Analysis | Feedback

George W. LeMaitre, Chairman & CEO

George W. LeMaitre has served as Chairman and Chief Executive Officer of LeMaitre Vascular Inc. since 2004, and as a member of its Board of Directors since 1992. Prior to his current role, he was an investment banking analyst at Lehman Brothers, an associate at the leveraged buyout firm McCown De Leeuw, and a credit analyst at Connecticut National Bank. The company was founded by his father, George D. LeMaitre, in 1983.

Dorian LeBlanc, C.P.A., Chief Financial Officer

Mr. LeBlanc joined LeMaitre Vascular as Chief Financial Officer in March 2025. Previously, he was the Chief Financial Officer of LumiraDx from 2016 until its acquisition by Roche Diagnostics in 2024, after which he became Roche's Group Head of Finance for the acquired LumiraDx business unit. He also served as Vice President, Global Operations and Chief Operating Officer of LumiraDx. Before LumiraDx, Mr. LeBlanc held several positions with Alere, a diagnostics company that was later acquired by Abbott, from 2007 to 2015.

David B. Roberts, President, Board Director

David B. Roberts has served as President of LeMaitre Vascular since 2007 and as a Board Director since 2001. He joined the company in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000, a position he held until 2007. Prior to joining LeMaitre, Mr. Roberts was Vice President of Development for BUCA, Inc., an operator of Buca di Beppo restaurants, from 1994 to 1997. From 1992 to 1994, he held various associate positions at Hancock Venture Partners and HarbourVest Partners, both private equity firms.

Trent G. Kamke, Senior Vice President, Operations

Trent G. Kamke has served as Senior Vice President, Operations of LeMaitre Vascular since 2005. He joined the company in 1997 as Quality Assurance Manager and then served as Vice President, Operations from 1999 to 2005. Before his tenure at LeMaitre, Mr. Kamke was employed by Haemonetics Corporation.

Andrew Hodgkinson, Senior Vice President, Clinical, Regulatory & Quality Affairs

Andrew Hodgkinson serves as the Senior Vice President of Clinical, Regulatory and Quality Affairs at LeMaitre Vascular.

AI Analysis | Feedback

The key risks to LeMaitre Vascular's business include regulatory hurdles, margin pressures, and the competitive landscape.

Key Risks to LeMaitre Vascular (LMAT)

Regulatory Hurdles: LeMaitre Vascular faces substantial regulatory challenges, particularly in Europe, due to the absence of a unified EU-wide approval process for certain allografts, such as its RestoreFlow product. This necessitates navigating individual country-by-country approval pathways, which is a more time-consuming and complex process than a single, overarching authorization. The EU's Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) also impose stricter compliance requirements that impact market access and product development timelines. Delays in securing these approvals can impede market entry and growth.
Margin Pressures: The company has experienced margin pressures stemming from a higher mix of lower-margin allograft products and increasing operating expenses, driven notably by sales force expansion, particularly in Europe. For instance, operating expenses saw a 20% rise in Q2 2025 compared to Q2 2024, and the company has experienced occasional misses in earnings per share (EPS). These factors can challenge the translation of robust sales into proportional profit improvements and potentially lead to stock price volatility.
Competitive Landscape and Market Disruption: LeMaitre Vascular operates in a crowded peripheral vascular device market that includes both large, established medical device companies and specialized firms. This intense competition can lead to significant pricing pressures. Furthermore, rival innovations constantly pose a threat, with the potential to render LeMaitre's existing product offerings obsolete.

AI Analysis | Feedback

null

AI Analysis | Feedback

LeMaitre Vascular's main products and their addressable market sizes are:

Vascular Grafts: The addressable market for vascular grafts is $3.7 billion globally.
Aggregate Market Revenue for 9 of 12 Markets where LeMaitre has a #1 or #2 Share: The aggregate market revenue for these markets is $1 billion globally.

AI Analysis | Feedback

LeMaitre Vascular (LMAT) is expected to drive future revenue growth over the next two to three years through several key strategies: * International Expansion of Key Products: The company is actively pursuing the international launch and approval of its products. A significant driver is the international rollout of Artegraft, which has already exceeded expectations and is anticipated to receive approvals in Canada and Korea in 2026. Similarly, RestoreFlow received German approval in October 2025, with distribution expected to commence in Q2 2026, and Irish approval is anticipated in the first half of 2026, which should accelerate approvals in other EU markets. These international market entries for established and recently approved products are critical to expanding LeMaitre's revenue base. * Growth in Core Product Categories: LeMaitre Vascular continues to see strong performance in its core product lines. Grafts and Shunts have been identified as significant growth drivers, with substantial year-over-year increases in sales. Specifically, the company highlights continued momentum in products like XenoSure, which is part of its patch category, as a key contributor to growth. * Strategic Price Increases: Pricing has played a notable role in LeMaitre Vascular's revenue growth and gross margin improvement. For example, price accounted for 10% of the Q3 2025 growth. The company's ability to implement higher average selling prices, driven by its differentiated product portfolio, is a consistent factor in its financial performance. * Expansion of Sales Force and International Presence: LeMaitre Vascular is investing in expanding its sales force and establishing new international offices to reach more customers. The company has been increasing its sales professional headcount and building out its sales management team. New international sales offices, such as the one in Shanghai that began shipping products in early 2025, and a new Paris sales office, underscore this commitment to direct market penetration and increased customer access globally. * Organic Growth from Existing Markets: Beyond specific product launches and international expansion, the company has consistently demonstrated strong organic sales growth across its regions, including EMEA (Europe, Middle East, and Africa), the Americas, and APAC (Asia-Pacific). This sustained organic growth indicates continued demand for its vascular devices and services within its established markets.

AI Analysis | Feedback

Share Repurchases

On February 21, 2024, LeMaitre Vascular's Board of Directors authorized a share repurchase program of up to $50.0 million of its common stock, valid until February 21, 2025, unless extended.
On February 18, 2025, the Board authorized a new repurchase program of up to $75.0 million of common stock, set to conclude on February 17, 2026, unless extended.

Share Issuance

LeMaitre Vascular announced a private offering of $150 million aggregate principal amount of 2.50% Convertible Senior Notes due 2030 on December 16, 2024.
The net proceeds from this offering are estimated to be approximately $145.9 million, or $167.8 million if initial purchasers fully exercise their option to purchase additional notes. These proceeds are intended for working capital and potential acquisitions or investments in complementary companies, product lines, or technologies.
Annual shares outstanding for LeMaitre Vascular increased from 20 million in 2020 to 23 million in 2024.

Outbound Investments

In 2020, LeMaitre Vascular acquired the business and assets of Artegraft, Inc. for $90.0 million.
The acquisition included $72.5 million in cash paid at closing ($65.0 million to Artegraft plus $7.5 million in escrow released December 31, 2021) and potential earnout payments of $17.5 million based on future sales.
The Artegraft acquisition was financed using available cash on hand and a $65.0 million senior secured credit facility.

Capital Expenditures

Property, Plant & Equipment increased from $31.1 million in fiscal year 2020 to $41.57 million in fiscal year 2024, and reached $42.5 million as of September 30, 2025.
The company continues to make investments in its sales force, new international offices, and regulatory approvals.

Better Bets than LeMaitre Vascular (LMAT)

INDUSTRY: Health Care Equipment

Higher Rev Chg 3Y Avg | Lower P/S (Values for LMAT: 14.6% | 7.9x)

BSX (15.6% | 7.4x)

Boston Scientific

DXCM (17.3% | 6.1x)

DexCom

GMED (45.6% | 4.3x)

Globus Medical

TMDX (105.9% | 7.6x)

TransMedics

INSP (37.7% | 3.2x)

Inspire Medical Systems

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for LMAT: 14.6% | 30.9x)

GMED (45.6% | 27.4x)

Globus Medical

UFPT (23.4% | 19.0x)

UFP Technologies

PDEX (17.8% | 12.2x)

Pro-Dex

Higher Rev Chg LTM (Value for LMAT: 13.1%)

MASI (38.5%)

Masimo

PODD (27.1%)

Insulet

ISRG (22.2%)

Intuitive Surgical

BSX (21.6%)

Boston Scientific

PEN (14.6%)

Penumbra

Higher Rev Chg 3Y Avg (Value for LMAT: 14.6%)

PODD (26.6%)

Insulet

DXCM (17.3%)

DexCom

PEN (17.2%)

Penumbra

ISRG (16.3%)

Intuitive Surgical

BSX (15.6%)

Boston Scientific

Higher Op Mgn LTM (Value for LMAT: 25.7%)

RMD (33.5%)

ResMed

IDXX (31.3%)

IDEXX Laboratories

ISRG (29.3%)

Intuitive Surgical

EW (27.5%)

Edwards Lifesciences

EMBC (27.4%)

Embecta

Higher CFO/Rev LTM (Value for LMAT: 30.4%)

UTMD (36.6%)

Utah Medical Products

RMD (35.8%)

ResMed

TMDX (31.4%)

TransMedics

ISRG (30.8%)

Intuitive Surgical

Higher FCF/Rev LTM (Value for LMAT: 27.5%)

UTMD (35.9%)

Utah Medical Products

RMD (33.4%)

ResMed

Higher Total Yield (Value for LMAT: 3.7%)

ABT (8.3%)

Abbott Laboratories

MDT (6.7%)

Medtronic

GEHC (6.0%)

GE HealthCare Technologies

BDX (5.1%)

Becton Dickinson

RMD (4.9%)

ResMed

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for LMAT: 14.6% | 7.9x)

BSX (15.6% | 7.4x)

Boston Scientific

DXCM (17.3% | 6.1x)

DexCom

UTHR (19.0% | 7.2x)

United Therapeutics

EXAS (15.5% | 6.2x)

Exact Sciences

MEDP (19.9% | 6.8x)

Medpace

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for LMAT: 14.6% | 30.9x)

UTHR (19.0% | 14.8x)

United Therapeutics

NBIX (24.6% | 26.4x)

Neurocrine Biosciences

GMED (45.6% | 27.4x)

Globus Medical

BMRN (15.5% | 18.8x)

BioMarin Pharmaceutical

ENSG (18.4% | 25.2x)

Ensign

Higher Rev Chg LTM (Value for LMAT: 13.1%)

LLY (36.8%)

Eli Lilly

ISRG (22.2%)

Intuitive Surgical

BSX (21.6%)

Boston Scientific

CI (20.9%)

Cigna

MCK (17.2%)

McKesson

Higher Rev Chg 3Y Avg (Value for LMAT: 14.6%)

ALNY (51.4%)

Alnylam Pharmaceuticals

LLY (23.4%)

Eli Lilly

INSM (22.8%)

Insmed

ISRG (16.3%)

Intuitive Surgical

BSX (15.6%)

Boston Scientific

Higher Op Mgn LTM (Value for LMAT: 25.7%)

LLY (43.0%)

Eli Lilly

GILD (38.3%)

Gilead Sciences

MRK (34.9%)

Merck

ISRG (29.3%)

Intuitive Surgical

JNJ (26.2%)

Johnson & Johnson

Higher CFO/Rev LTM (Value for LMAT: 30.4%)

AMGN (36.5%)

Amgen

ABBV (35.0%)

AbbVie

GILD (33.2%)

Gilead Sciences

VRTX (31.7%)

Vertex Pharmaceuticals

ISRG (30.8%)

Intuitive Surgical

Higher FCF/Rev LTM (Value for LMAT: 27.5%)

ABBV (33.0%)

AbbVie

AMGN (32.1%)

Amgen

BMY (31.9%)

Bristol-Myers Squibb

GILD (31.5%)

Gilead Sciences

VRTX (28.5%)

Vertex Pharmaceuticals

Higher Total Yield (Value for LMAT: 3.7%)

MRK (10.2%)

Merck

UNH (8.6%)

UnitedHealth

ABT (8.3%)

Abbott Laboratories

JNJ (7.5%)

Johnson & Johnson

AMGN (6.7%)

Amgen

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for LMAT: 14.6% | 7.9x)

BRK-B (19.8% | 2.7x)

Berkshire Hathaway

GE (15.7% | 7.6x)

GE Aerospace

MU (28.3% | 7.6x)

Micron Technology

BKNG (17.8% | 6.8x)

Booking

UBER (19.6% | 3.4x)

Uber Technologies

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for LMAT: 14.6% | 30.9x)

META (17.3% | 20.5x)

Meta Platforms

MU (28.3% | 23.4x)

Micron Technology

BKNG (17.8% | 19.6x)

Booking

NEM (23.9% | 12.3x)

Newmont

AEM (26.0% | 17.4x)

Agnico Eagle Mines

Higher Rev Chg LTM (Value for LMAT: 13.1%)

NVDA (65.2%)

NVIDIA

AVGO (23.9%)

Broadcom

META (21.3%)

Meta Platforms

MSFT (15.6%)

Microsoft

GOOGL (13.4%)

Alphabet

Higher Rev Chg 3Y Avg (Value for LMAT: 14.6%)

NVDA (91.6%)

NVIDIA

PLTR (29.3%)

Palantir Technologies

AVGO (25.2%)

Broadcom

BRK-B (19.8%)

Berkshire Hathaway

META (17.3%)

Meta Platforms

Higher Op Mgn LTM (Value for LMAT: 25.7%)

NVDA (58.8%)

NVIDIA

MSFT (46.3%)

Microsoft

META (43.2%)

Meta Platforms

GOOGL (32.2%)

Alphabet

AAPL (31.9%)

Apple

Higher CFO/Rev LTM (Value for LMAT: 30.4%)

META (56.8%)

Meta Platforms

MSFT (50.0%)

Microsoft

NVDA (44.4%)

NVIDIA

AVGO (43.1%)

Broadcom

GOOGL (39.3%)

Alphabet

Higher FCF/Rev LTM (Value for LMAT: 27.5%)

V (53.9%)

Visa

MA (52.5%)

Mastercard

PLTR (46.0%)

Palantir Technologies

AVGO (42.1%)

Broadcom

NVDA (41.3%)

NVIDIA

Higher Total Yield (Value for LMAT: 3.7%)

XOM (9.2%)

Exxon Mobil

JPM (6.4%)

JPMorgan Chase

BRK-B (6.2%)

Berkshire Hathaway

V (5.1%)

Visa

META (3.8%)

Meta Platforms

		Best Bets In Health Care Sector
	LMAT	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	35.8	22.2	13.5	32.5	13.8	11.9	79.4	74.9	28.1	11.4	58.7
P/EBIT	26.2	10.7	10.5	33.3	11.6	9.0	57.8	73.1	27.4	7.6	68.2
What You Get
Rev Chg Q	11.4%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	13.1%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	14.6%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	18.5%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	LeMaitre Vascular Earnings Notes
2	How Low Can LeMaitre Vascular Stock Really Go?	Return
3	Is LMAT Stock Still the Best Pick Among Its Peers?
4	Better Bet Than LMAT Stock: Pay Less Than LeMaitre Vascular To Get More From GMED, UFPT	Actionable
5	Why LeMaitre Vascular Stock Moved: LMAT Stock Has Gained 90% Since 2022 Fiscal End, Primarily Due To Favorable Change In Revenues
6	LMAT Dip Buy Analysis
7	LeMaitre Vascular (LMAT) Valuation Ratios Comparison	Financials
8	LeMaitre Vascular Total Shareholder Return (TSR): 64.4% in 2024 and 24.4% 3-yr compounded annual returns (above peer average)
9	Should You Buy LeMaitre Vascular Stock?	Buy or Fear
10	LeMaitre Vascular (LMAT) Operating Cash Flow Comparison	Financials

	Title
0	ARTICLES

Trade Ideas

Select ideas related to LMAT. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.1%	21.1%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-6.7%	-6.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	16.7%	16.7%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	11.8%	11.8%	-5.1%
LMAT_7312021_Quality_Momentum_RoomToRun_10%	07312021	LMAT	LeMaitre Vascular	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	-24.4%	-6.7%	-27.8%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
OMER	Omeros	0.9	75.5%	55.5%
DVAX	Dynavax Technologies	1.8	38.2%	20.4%
EWTX	Edgewise Therapeutics	2.9	25.5%	2.2%
AGIO	Agios Pharmaceuticals	1.7	18.6%	-11.2%
TVTX	Travere Therapeutics	3.6	13.9%	131.2%
KOD	Kodiak Sciences	1.6	13.2%	212.4%
RZLT	Rezolute	0.3	13.2%	-44.1%
UP	Wheels Up Experience	0.5	11.7%	-57.4%
FBYD	Falcons Beyond Global	0.7	9.5%	129.7%
BW	Babcock & Wilcox Enterprises	0.5	8.5%	226.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ASTS	AST SpaceMobile	18.9	-8.9%	269.9%
QBTS	D-Wave Quantum	9.4	-5.5%	227.6%
NNE	Nano Nuclear Energy	1.2	-4.6%	21.7%
MNMD	Mind Medicine	1.2	-4.2%	93.0%
PPTA	Perpetua Resources	2.0	-4.0%	149.1%
KOS	Kosmos Energy	0.4	-4.0%	-73.6%
FRMI	Fermi	5.5	-4.0%	-75.7%
EXOD	Exodus Movement	0.4	-3.9%	-50.5%
TLRY	Tilray Brands	10.8	-3.6%	-23.7%
AEHR	Aehr Test Systems	0.7	-3.1%	32.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	74.0%	55.5%
LUNR	Intuitive Machines	2.0	63.7%	-8.0%
AAOI	Applied Optoelectronics	2.6	51.1%	11.2%
FBYD	Falcons Beyond Global	0.7	47.2%	129.7%
FLY	Firefly Aerospace	3.8	45.9%	-55.2%
RKLB	Rocket Lab	39.8	43.0%	203.0%
DVAX	Dynavax Technologies	1.8	42.5%	20.4%
UAMY	United States Antimony	0.8	39.9%	258.8%
DJT	Trump Media & Technology	4.0	36.7%	-58.0%
RZLT	Rezolute	0.3	36.3%	-44.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	31.7	-80.5%	-28.0%
TPL	Texas Pacific Land	6.8	-66.5%	-19.2%
LW	Lamb Weston	6.0	-28.6%	-34.8%
TLRY	Tilray Brands	10.8	-21.2%	-23.7%
INSP	Inspire Medical Systems	2.8	-19.1%	-48.4%
TDUP	ThredUp	0.8	-17.1%	354.7%
OLMA	Olema Pharmaceuticals	2.3	-15.8%	370.8%
IIPR	Innovative Industrial Properties	1.4	-12.9%	-15.7%
ABM	ABM Industries	2.6	-12.6%	-15.8%
FRMI	Fermi	5.5	-12.6%	-75.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	3.0	144.6%	47.5%
TE	T1 Energy	1.1	124.5%	418.4%
ANF	Abercrombie & Fitch	6.0	93.2%	-15.2%
VERA	Vera Therapeutics	3.6	90.4%	31.6%
LUNR	Intuitive Machines	2.0	85.7%	-8.0%
AAOI	Applied Optoelectronics	2.6	82.5%	11.2%
RKLB	Rocket Lab	39.8	81.8%	203.0%
PL	Planet Labs PBC	6.2	76.1%	403.0%
NRGV	Energy Vault	0.8	66.9%	118.9%
FLY	Firefly Aerospace	3.8	60.4%	-55.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-44.1%
JANX	Janux Therapeutics	0.9	-54.6%	-73.3%
LENZ	LENZ Therapeutics	0.5	-46.3%	-40.6%
FRMI	Fermi	5.5	-45.2%	-75.7%
GOGO	Gogo	0.6	-34.1%	-43.0%
HPK	HighPeak Energy	0.6	-30.8%	-69.2%
ORIC	ORIC Pharmaceuticals	0.7	-28.5%	4.5%
FDMT	4D Molecular Therapeutics	0.5	-25.6%	45.4%
NKTR	Nektar Therapeutics	0.6	-25.1%	215.0%
LW	Lamb Weston	6.0	-24.8%	-34.8%

Peer Comparisons for LeMaitre Vascular

Peers to compare with:

Financials

	LMAT	ANGO	AORT	TFX	PEN	MDT	Median
Name	LeMaitre.	AngioDyn.	Artivion	Teleflex	Penumbra	Medtronic
Mkt Price	84.34	13.16	46.89	122.33	315.86	97.27	90.81
Mkt Cap	1.9	0.5	2.2	5.4	12.3	124.7	3.8
Rev LTM	241	301	423	3,190	1,334	34,758	878
Op Inc LTM	62	-23	22	561	173	6,719	117
FCF LTM	66	-12	18	264	153	5,206	109
FCF 3Y Avg	41	-14	8	365	111	4,917	76
CFO LTM	73	-8	30	391	203	7,113	138
CFO 3Y Avg	48	-10	20	478	140	6,626	94

Growth & Margins

	LMAT	ANGO	AORT	TFX	PEN	MDT	Median
Name	LeMaitre.	AngioDyn.	Artivion	Teleflex	Penumbra	Medtronic
Rev Chg LTM	13.1%	2.7%	9.8%	5.4%	14.6%	5.3%	7.6%
Rev Chg 3Y Avg	14.6%	-1.8%	10.5%	4.5%	17.2%	4.1%	7.5%
Rev Chg Q	11.4%	12.2%	18.4%	19.4%	17.8%	6.6%	15.0%
QoQ Delta Rev Chg LTM	2.7%	2.8%	4.3%	4.9%	4.2%	1.6%	3.5%
Op Mgn LTM	25.7%	-7.7%	5.3%	17.6%	13.0%	19.3%	15.3%
Op Mgn 3Y Avg	22.4%	-8.4%	4.4%	18.3%	8.6%	18.6%	13.5%
QoQ Delta Op Mgn LTM	2.4%	0.5%	0.9%	-1.9%	0.5%	-0.1%	0.5%
CFO/Rev LTM	30.4%	-2.6%	7.2%	12.3%	15.2%	20.5%	13.7%
CFO/Rev 3Y Avg	21.8%	-3.3%	5.2%	15.7%	11.6%	19.9%	13.6%
FCF/Rev LTM	27.5%	-4.0%	4.1%	8.3%	11.4%	15.0%	9.9%
FCF/Rev 3Y Avg	18.5%	-4.8%	2.0%	12.0%	9.2%	14.8%	10.6%

Valuation

	LMAT	ANGO	AORT	TFX	PEN	MDT	Median
Name	LeMaitre.	AngioDyn.	Artivion	Teleflex	Penumbra	Medtronic
Mkt Cap	1.9	0.5	2.2	5.4	12.3	124.7	3.8
P/S	7.9	1.8	5.2	1.7	9.3	3.6	4.4
P/EBIT	26.2	-23.3	98.7	-23.5	66.0	19.5	22.8
P/E	35.8	-16.9	-242.3	-16.5	75.3	26.2	4.8
P/CFO	26.1	-69.6	72.7	13.8	60.7	17.5	21.8
Total Yield	3.7%	-5.9%	-0.4%	-5.5%	1.3%	6.7%	0.5%
Dividend Yield	0.9%	0.0%	0.0%	0.6%	0.0%	2.9%	0.3%
FCF Yield 3Y Avg	2.3%	-4.2%	0.4%	4.3%	1.3%	4.3%	1.8%
D/E	0.1	0.0	0.1	0.5	0.0	0.2	0.1
Net D/E	-0.1	-0.1	0.1	0.4	-0.0	0.2	0.0

Returns

	LMAT	ANGO	AORT	TFX	PEN	MDT	Median
Name	LeMaitre.	AngioDyn.	Artivion	Teleflex	Penumbra	Medtronic
1M Rtn	0.1%	7.0%	2.4%	9.8%	6.0%	-5.7%	4.2%
3M Rtn	-3.7%	22.8%	14.6%	-0.5%	24.5%	1.6%	8.1%
6M Rtn	0.2%	28.9%	53.2%	3.3%	24.7%	14.9%	19.8%
12M Rtn	-8.1%	51.4%	64.2%	-30.2%	31.4%	23.2%	27.3%
3Y Rtn	89.3%	-0.9%	296.4%	-49.7%	43.8%	37.4%	40.6%
1M Excs Rtn	-3.3%	3.6%	-1.0%	6.4%	2.6%	-9.1%	0.8%
3M Excs Rtn	-5.1%	19.3%	11.0%	-0.1%	21.8%	-1.8%	5.5%
6M Excs Rtn	-10.1%	20.5%	40.3%	-10.0%	11.7%	1.8%	6.7%
12M Excs Rtn	-24.5%	31.2%	47.8%	-47.5%	13.3%	7.1%	10.2%
3Y Excs Rtn	7.9%	-78.3%	196.9%	-130.1%	-37.9%	-42.3%	-40.1%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/7/2025	2/28/2025	2/29/2024	3/1/2023	2/28/2022	3/12/2021	3/12/2020
Key Financials
Total Revenue	241	220	193	162	154	129	117
EBITDA	83	67	49	37	48	37	27
Operating Income	62	52	37	30	36	28	21
Net Income	53	44	30	21	27	21	18
EPS	2.37	1.96	1.36	0.94	1.27	1.05	0.91
Growth Rates
Total Revenue Growth	13.1%	13.6%	19.7%	4.7%	19.4%	10.4%	11.0%
EBITDA Growth	28.2%	36.3%	32.7%	-22.4%	28.4%	36.8%	-17.3%
Operating Income Growth	24.8%	40.5%	24.3%	-17.8%	28.6%	33.7%	2.2%
Net Income Growth	29.1%	46.3%	45.9%	-23.3%	26.8%	18.3%	-21.8%
Margins
EBITDA Margin	34.6%	30.4%	25.3%	22.8%	30.8%	28.6%	23.1%
Operating Income Margin	25.7%	23.8%	19.2%	18.5%	23.6%	21.9%	18.1%
Net Income Margin	22.1%	20.0%	15.6%	12.8%	17.4%	16.4%	15.3%
Cash & Debt
Total Cash	343	300	105	83	70	27	33
Total Debt	186	186	19	17	16	55	16
Net Debt / (Cash)	-157	-114	-86	-66	-54	28	-17
Cash Flows
Net Cash from Operations	73	44	37	25	35	35	14
Free Cash from Operations	66	37	29	22	30	32	10
Returns to Shareholders
Dividends	17	14	12	11	9	8	7
Share Repurchases	-0	-0	-0	1	1	1	1

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/7/2025	8/6/2025	5/8/2025	2/28/2025	11/8/2024	8/8/2024	5/10/2024	2/29/2024	11/7/2023	8/8/2023	5/9/2023	3/1/2023
Key Financials Quarterly
Total Revenue	61	64	60	56	55	56	53	49	47	50	47	41
Ebitda	26	22	18	17	17	18	15	15	12	12	11	7
Operating Income	20	16	13	13	13	14	12	10	9	10	8	7
Net Income	17	14	11	11	11	12	10	8	8	8	6	6
EPS	0.77	0.61	0.49	0.50	0.50	0.53	0.44	0.38	0.34	0.36	0.27	0.26
Key Financials TTM
Total Revenue TTM	241	235	226	220	213	206	200	193	186	177	169	162
Ebitda TTM	83	74	70	67	65	60	54	49	41	38	37	37
Operating Income TTM	62	55	53	52	50	46	41	37	34	31	30	30
Net Income TTM	53	47	45	44	41	38	34	30	27	25	21	21
Growth Rates Quarterly
Total Revenue Growth	11.4%	15.0%	12.0%	14.0%	15.6%	11.4%	13.6%	19.4%	21.5%	19.0%	19.0%	3.7%
EBITDA Growth	56.0%	23.1%	19.1%	11.9%	46.7%	49.6%	44.2%	119.2%	36.5%	5.5%	2.2%	-39.8%
Operating Income Growth	54.5%	12.3%	6.3%	25.9%	43.2%	49.3%	45.2%	46.5%	49.3%	8.3%	3.2%	-16.1%
Net Income Growth	55.8%	16.5%	11.4%	32.1%	48.5%	46.0%	63.7%	50.4%	37.5%	130.4%	0.0%	-8.9%
Margins Quarterly
EBITDA Margin	43.4%	34.3%	30.2%	30.0%	31.0%	32.0%	28.4%	30.5%	24.4%	23.9%	22.4%	16.6%
Operating Income Margin	33.3%	25.1%	21.1%	23.1%	24.0%	25.7%	22.2%	20.9%	19.4%	19.2%	17.4%	17.0%
Net Income Margin	28.4%	21.5%	18.4%	20.1%	20.3%	21.2%	18.5%	17.3%	15.8%	16.2%	12.8%	13.7%
Cash & Debt
Total Cash	343	319	303	300	124	113	108	105	97	90	81	83
Total Debt	186	186	185	186	18	18	19	19	17	17	17	17
Net Debt / (Cash)	-157	-134	-117	-114	-106	-95	-89	-86	-80	-73	-64	-66
Cash Flows Quarterly
FCF from Operations	29	20	9	15	14	10	5	11	12	12	2	4
Cash Flows TTM
FCF from Operations TTM	73	59	48	44	40	37	40	37	30	26	23	25
Returns to Shareholders Quarterly
Dividends	5	5	5	4	4	4	4	3	3	3	3	3
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	197.7%	94.6%	62.4%	65.6%	54.6%	54.4%	44.2%	37.0%	32.9%	33.0%	25.7%	22.0%
Return on Invested Capital (ROIC) TTM
ROIC TTM	151.7%	81.5%	65.6%	64.7%	51.3%	43.1%	37.7%	34.3%	30.2%	26.4%	23.7%	24.6%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Development, manufacturing, and marketing of medical devices and implants, as well as the processing	193
Single segment		162	154	129	117
Total	193	162	154	129	117

Price Behavior

Price Behavior

Market Price	$84.34
Market Cap ($ Bil)	1.9
First Trading Date	10/19/2006
Distance from 52W High	-18.2%
	50 Days	200 Days
DMA Price	$86.09	$85.93
DMA Trend	down	down
Distance from DMA	-2.0%	-1.8%
	3M	1YR
Volatility	23.0%	32.8%
Downside Capture	52.35	68.57
Upside Capture	23.88	50.09
Correlation (SPY)	17.6%	39.3%

LMAT Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.32	0.34	0.53	0.83	0.66	0.77
Up Beta	-0.71	-0.13	0.24	1.29	0.75	0.73
Down Beta	-0.14	0.93	0.55	0.58	0.65	0.71
Up Capture	7%	-1%	9%	57%	27%	64%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	7	16	25	63	125	390
Down Capture	95%	39%	100%	94%	80%	93%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	13	26	38	63	124	356

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of LMAT With Other Asset Classes (Last 1Y)
	LMAT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-7.7%	16.4%	19.2%	71.9%	8.9%	6.0%	-10.4%
Annualized Volatility	32.6%	17.3%	19.5%	19.3%	15.3%	17.1%	35.0%
Sharpe Ratio	-0.21	0.72	0.78	2.69	0.36	0.18	-0.12
Correlation With Other Assets		28.9%	39.2%	1.4%	10.3%	40.1%	14.2%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of LMAT With Other Asset Classes (Last 5Y)
	LMAT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	19.3%	8.6%	14.9%	18.7%	11.7%	4.8%	32.6%
Annualized Volatility	35.4%	14.5%	17.1%	15.5%	18.7%	18.9%	48.7%
Sharpe Ratio	0.58	0.41	0.70	0.97	0.51	0.17	0.59
Correlation With Other Assets		32.7%	38.1%	6.3%	4.2%	34.2%	21.3%

Based On 10-Year Data

		Comparison of LMAT With Other Asset Classes (Last 10Y)
	LMAT	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	18.9%	9.8%	14.7%	14.9%	6.9%	5.2%	69.2%
Annualized Volatility	41.6%	16.6%	18.0%	14.8%	17.6%	20.8%	55.8%
Sharpe Ratio	0.56	0.48	0.70	0.83	0.31	0.22	0.90
Correlation With Other Assets		37.7%	39.4%	2.7%	9.9%	34.0%	15.0%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	1,129,732
Short Interest: % Change Since 11302025	4.2%
Average Daily Volume	177,204
Days-to-Cover Short Interest	6.38
Basic Shares Quantity	22,660,000
Short % of Basic Shares	5.0%

Returns Analyses

	Title
0	How Low Can LeMaitre Vascular Stock Really Go?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/6/2025	1.4%	5.0%	-3.0%
8/5/2025	8.9%	10.3%	13.6%
2/27/2025	-8.1%	-17.4%	-16.7%
10/31/2024	7.3%	14.3%	19.5%
8/1/2024	-1.4%	-3.8%	4.9%
2/27/2024	14.4%	8.6%	8.5%
11/1/2023	-2.4%	3.4%	12.9%
8/1/2023	3.0%	-9.1%	-6.4%
...
SUMMARY STATS
# Positive	10	10	10
# Negative	9	9	9
Median Positive	5.2%	4.8%	6.7%
Median Negative	-8.1%	-8.7%	-8.4%
Max Positive	14.4%	14.3%	19.5%
Max Negative	-19.5%	-18.0%	-26.8%

	Forward Returns
11/6/2025	1.4%	5.0%	-3.0%
8/5/2025	8.9%	10.3%	13.6%
2/27/2025	-8.1%	-17.4%	-16.7%
10/31/2024	7.3%	14.3%	19.5%
8/1/2024	-1.4%	-3.8%	4.9%
2/27/2024	14.4%	8.6%	8.5%
11/1/2023	-2.4%	3.4%	12.9%
8/1/2023	3.0%	-9.1%	-6.4%
2/23/2023	1.8%	4.1%	3.9%
10/27/2022	-19.1%	-14.0%	-13.6%
7/28/2022	3.1%	10.4%	2.5%
2/24/2022	1.3%	4.6%	-1.5%
10/28/2021	-7.5%	-7.4%	-14.8%
7/13/2021	-9.2%	-8.7%	-8.4%
2/25/2021	10.6%	0.8%	0.8%
10/29/2020	-8.6%	-2.5%	11.1%
7/23/2020	10.3%	4.5%	1.2%
4/30/2020	-7.4%	-8.0%	-5.4%
2/6/2020	-19.5%	-18.0%	-26.8%
SUMMARY STATS
# Positive	10	10	10
# Negative	9	9	9
Median Positive	5.2%	4.8%	6.7%
Median Negative	-8.1%	-8.7%	-8.4%
Max Positive	14.4%	14.3%	19.5%
Max Negative	-19.5%	-18.0%	-26.8%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11072025	10-Q 9/30/2025
6302025	8062025	10-Q 6/30/2025
3312025	5082025	10-Q 3/31/2025
12312024	2282025	10-K 12/31/2024
9302024	11082024	10-Q 9/30/2024
6302024	8082024	10-Q 6/30/2024
3312024	5102024	10-Q 3/31/2024
12312023	2292024	10-K 12/31/2023
9302023	11072023	10-Q 9/30/2023
6302023	8082023	10-Q 6/30/2023
3312023	5092023	10-Q 3/31/2023
12312022	3012023	10-K 12/31/2022
9302022	11082022	10-Q 9/30/2022
6302022	8052022	10-Q 6/30/2022
3312022	5102022	10-Q 3/31/2022
12312021	2282022	10-K 12/31/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Equipment Resources

MedTech Dive

MassDevice

Fierce Medical Devices

Medical Device and Diagnostic Industry

MD+DI

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

LeMaitre Vascular (LMAT)

Market Price (12/25/2025): $84.32 | Market Cap: $1.9 BilSector: Health Care | Industry: Health Care Equipment

LeMaitre Vascular (LMAT)

Market Price (12/25/2025): $84.32Market Cap: $1.9 BilSector: Health CareIndustry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

LMAT Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About LeMaitre Vascular (LMAT)

Key Risks to LeMaitre Vascular (LMAT)

Share Repurchases

Share Issuance

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than LeMaitre Vascular (LMAT)

INDUSTRY: Health Care Equipment

Higher Rev Chg 3Y Avg | Lower P/S (Values for LMAT: 14.6% | 7.9x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for LMAT: 14.6% | 30.9x)

Higher Rev Chg LTM (Value for LMAT: 13.1%)

Higher Rev Chg 3Y Avg (Value for LMAT: 14.6%)

Higher Op Mgn LTM (Value for LMAT: 25.7%)

Higher CFO/Rev LTM (Value for LMAT: 30.4%)

Higher FCF/Rev LTM (Value for LMAT: 27.5%)

Higher Total Yield (Value for LMAT: 3.7%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for LMAT: 14.6% | 7.9x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for LMAT: 14.6% | 30.9x)

Higher Rev Chg LTM (Value for LMAT: 13.1%)

Higher Rev Chg 3Y Avg (Value for LMAT: 14.6%)

Higher Op Mgn LTM (Value for LMAT: 25.7%)

Higher CFO/Rev LTM (Value for LMAT: 30.4%)

Higher FCF/Rev LTM (Value for LMAT: 27.5%)

Higher Total Yield (Value for LMAT: 3.7%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for LMAT: 14.6% | 7.9x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for LMAT: 14.6% | 30.9x)

Higher Rev Chg LTM (Value for LMAT: 13.1%)

Higher Rev Chg 3Y Avg (Value for LMAT: 14.6%)

Higher Op Mgn LTM (Value for LMAT: 25.7%)

Higher CFO/Rev LTM (Value for LMAT: 30.4%)

Higher FCF/Rev LTM (Value for LMAT: 27.5%)

Higher Total Yield (Value for LMAT: 3.7%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for LeMaitre Vascular

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Market Price (12/25/2025): $84.32 | Market Cap: $1.9 Bil
Sector: Health Care | Industry: Health Care Equipment

Market Price (12/25/2025): $84.32
Market Cap: $1.9 Bil
Sector: Health Care
Industry: Health Care Equipment